Keyword: Axovant Sciences
The midphase Type 2 diabetes candidate slots into the pipeline of Roivant’s newly minted cardiometabolic disease startup Metavant.
Axovant CEO Hung resigned, Arcturus CSO and COO Chivukula stepped down, Celgene spinoff emerged with Bob Hariri at the reins.
After a very brief and tumultuous tenure at startup Axovant with big hopes and backing, former Medivation chief David Hung, M.D., has resigned as CEO.
The deal ends Poxel’s long wait for a partner capable of running a late-phase diabetes program and starts Roivant’s expansion into metabolic diseases.
David Hung's decision to join Axovant after selling Medivation to Pfizer for $14 billion now looks more like a gamble that isn't paying off.
Last year, a quiet J.P. Morgan Healthcare Conference meant few deals, few major updates. That set the tone for much of the year on the M&A front.
Axovant’s run of bad news shows no signs of letting up, with negative results in a phase 2b trial spelling the end for lead candidate intepirdine.
Roivant’s Vivek Ramaswamy didn't sugarcoat its Alzheimer’s flop but said his company won't back away from the field.
The deal gives Roivant, Axovant’s parent company, another part-developed, unloved drug to try to turn into a star.
Axovant becomes the latest company to see a major miss in Alzheimer's.